ecause the activity of mitochondrial glycerol phosphate dehydrogenase (mGPD) in the pancreatic 3-cell is normally among the highest of the body, but is low in the pancreatic islets of numerous rodent models of NIDDM and is reported to be low in the islets of the few humans studied with NIDDM (1,2), it has been questioned whether mGPD might be a diabetes candidate gene. Linkage studies have failed to find an association between mGPD and NIDDM in Caucasians (3) and Mexican Americans (4), which suggests that mutations in mGPD are not a common cause of NIDDM. Since NIDDM is a multifactorial and heterogeneous disorder, it is possible that abnormalities in many individual genes influencing reactions that are important for the maintenance of normal glucose homeostasis in the (3-cell will be found in a low percentage of individuals with NIDDM. With this idea in mind, conditions for using single-stranded conformational polymorphism (SSCP) analysis of the mGPD gene were developed to use this method to screen for mutations in this gene.
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Initial screening of all 18 exons of mGPD in 39 Caucasian individuals with NIDDM (age range at diagnosis, 31-88 years; mean ± SD, 51 ± 13 years) from the University of Wisconsin was unremarkable, except for exon 6 of subject 30 (a 63-year-old nonobese man with an onset of NIDDM at age 53, who also received treatment for hyperlipidemia and hypertension). Two sisters, ages 69 and 72, and one brother, age 63, of subject 30, none of whom had diabetes, also possessed the mutation as judged by SSCP analysis. DNA sequencing showed that all four individuals were heterozygous for the mutation. DNA available at the Rockefeller University from a separate set of 48 NIDDM subjects with an early or late onset Received for publication 15 October 1996 and accepted in revised form 13 June 1997.
Additional information can be found in the on-line appendix at www.diabetes.org/diabetes/appendix.htm. mGPD, mitochondrial glycerol phosphate dehydrogenase; SSCP, singlestranded conformational polymorphism.
of NIDDM from various ethnic groups was also screened for mutations at the critical sites of the enzyme (the FAD-, substrate-, and calcium-binding sites [exons 3,4,6,10,11,15, and 16]), and no mutations were found. SSCP analysis of exon 6 in an additional unrelated 18 Caucasian individuals with NIDDM from Wisconsin, including a 61-year-old first cousin of subject 30, was normal. Additional information about these subjects can be found in the on-line appendix at www.diabetes.org/diabetes/appendix.htm.
The mutation at nucleotide 737 of the cDNA is a CT conversion, with a resulting nonconservative replacement of proline with leucine at position 205 of the protein. The proline at position 205 is conserved in humans (5), rats, mice, yeast, Bacillus subtilis, and Escherichia coli, and >15 amino acids on either side of this proline are conserved in humans, rats, and mice. This region and other mutations in mGPD reported to date are, with one exception, within a segment between amino acid residues 167 and 304 tentatively identified as most likely being the only segment of the protein that is situated in the mitochondrial matrix (6). This region is not near the FAD-, glycerol phosphate-, or calcium-binding regions of the protein. Since the proline at position 205 is conserved even in bacteria and yeast, it seems likely that this amino acid is critical for the normal functioning of the protein.
The results of the current study confirm that mutations in mGPD are unlikely to be a common cause of NIDDM in Caucasians, but do not completely rule out mutations in mGPD contributing to diabetes in a very small percentage of individuals with NIDDM. Takeuchi et al. (7) recently reported four mutations in mGPD, detected by SSCP screening of the coding region of 100 Japanese patients with NIDDM. Their analysis did not include either the 5' untranslated region (exons 1A and IB) or the known 3' untranslated region of the gene. Two mutations did not change the amino acid encoded and were thus silent. A third mutation at position 264 was not conserved in mammals, which makes it unlikely that it is etiologically significant in NIDDM. This mutation converts a histidine codon to one encoding arginine, which is normal at this position in the mouse and rat. Another mutation at position 306 of the protein is at a position and within a region that is unusually variable for mGPD. Novials et al. (9) recently reported mutations affecting the amino acid sequence of the calcium-binding domain of mGPD in a man with NIDDM and low mGPD activity in his peripheral lymphocytes. His glucoseintolerant half-sister also possessed these mutations, but his diabetic brother did not. 1660 DIABETES, VOL. 46, OCTOBER 1997 Since the siblings of subject 30 possess the mutation at position 205 of mGPD and are not diabetic, mGPD may not contribute to NIDDM in subject 30, or more than this mutation might be required for diabetes. If diabetes in this individual is to be explained on the basis of the mutation in mGPD, it is necessary to invoke the idea that the mutation in one copy of the mGPD gene interferes with normal 3-cell mGPD activity, but that this alone is not sufficient to cause NIDDM. That is, if impaired mGPD activity causes impaired insulin secretion, other factors, perhaps insulin resistance, are necessary to bring out the expression of inadequate insulin secretion. According to this scenario, the nondiabetic siblings' insulin secretory reserve might be inadequate, but not expressed due to the lack of other factors, such as insulin resistance, that might challenge the pancreatic reserve.
